<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13417">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02088307</url>
  </required_header>
  <id_info>
    <org_study_id>CARDIOLIFE--001</org_study_id>
    <nct_id>NCT02088307</nct_id>
  </id_info>
  <brief_title>Study of the Cardiovascular Vitamin, CardioLife</brief_title>
  <official_title>Evaluation of the Metabolic and Physiological Profiles of Patients Diagnosed With Cardiovascular Disease (CVD) Following Administration of the Novel Cardiovascular Vitamin, CardioLife</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the metabolic and physiological characteristics of patients with diagnosed
      Cardiovascular Disease following administration of the Cardiovascular vitamin, CardioLife.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum lipid levels</measure>
    <time_frame>Baseline to 6 Months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change plasma levels of endothelial progenitor cells (EPC)</measure>
    <time_frame>Baseline to 6 Months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cholesterol levels</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in homocysteine levels</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in erythrocyte sedimentation rate (ESR) levels</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hs-C-reactive protein (CRP) levels</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects in the control arm will not receive an intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CardioLife</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The main ingredients in the CardioLife supplements are as follows: garlic, co-enzyme Q10, arjuna, hawthorn, guggul, red yeast rice, policosanol, nattokinase, tumeric/curcumin, ashwangandha, L-carnitine, grape seed extract and vitamin B12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>CardioLife</intervention_name>
    <arm_group_label>CardioLife</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 - 90 years old and ability to understand the planned study.

          -  Patients with Cardiovascular Disease

          -  Able to comply with all study-related visits

          -  Able to give Informed Consent

          -  Negative for HcG with a serum pregnancy test

          -  If the patient has diabetes mellitus it must be controlled (HbA1c &lt; 9.0%)

          -  Life expectancy of 1 year or more in the opinion of the investigator.

          -  Hematocrit ≥ 28.0%, White Blood Cell count ≤ 14,000, Platelet count ≥ 50,000, Serum
             bilirubin, ALT, AST x 2.5 time the upper level of normal.

          -  Controlled blood pressure (systolic blood pressure ≤160 and a diastolic blood
             pressure of ≤100 mmHG) and established anti-hypertensive therapy as necessary prior
             to entry into the study

          -  Patient must be on at least three of the listed medications for at least 30 days with
             no new medications to treat the disease introduced in the last month. Medications
             are: Anti-Platelet Therapy, Beta-Blockers, ACE/ARB, Calcium Blocker, Nitrates, After
             Load Reducing Agents, Lipid Lowering Agents, and/or Diuretics.   Cardiac medications
             must be at stable doses with no dose change within the last 30 days.

        Pre-existing condition (e.g. thromboembolic risk, diabetes, hypercholesterolemia are
        adequately controlled in the opinion of the investigator)

          -  Fertile patients (male and female) must agree to use an appropriate form of
             contraception while participating in the study.

        Exclusion Criteria:

          -  Female who is pregnant or nursing, or of child bearing potential and is not using a
             reliable birth control method, or who intend to become pregnant during the tenure of
             this study.

          -  End stage renal disease (Creatinine ≤ 3.0 mg / dl) and/or dialysis

          -  Acute Myocardial Infarction 90 days prior to randomization.

          -  Inability or unwillingness to comply with the treatment protocol, follow-up, research
             tests, or give consent.

          -  Life expectancy &lt;1 year due to concomitant illnesses

          -  Known cancer or malignancy within the last 5 years

          -  Prior admission for substance abuse

          -  Uncontrolled lipid levels as determined by the Investigator

          -  Untreated Hypothyroidism

          -  Known Congenital Heart Defects

          -  History of Ischemic and Non-Ischemic Cardiomyopathy or Heart Failure

          -  Body Mass Index (BMI) of 45 kg/m2 or greater

          -  Medication use of steroids 30 days prior to enrollment

          -  Current use of any Nutraceutical that contains ingredients known to affect blood
             pressure, or any active ingredients that are found in CardioLifeTM

          -  Patient receiving experimental medication or participating in another clinical study
             within 30 days of signing the informed consent

          -  In the opinion of the investigator or the sponsor, the patient is unsuitable for
             cellular therapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anwar Tandar, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle Esplin, BS</last_name>
    <phone>801-585-5243</phone>
    <email>Michelle.Esplin@hsc.utah.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Utah Hospitals and Clinics</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Esplin, BS</last_name>
      <phone>801-585-5243</phone>
      <email>Michelle.Esplin@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Anwar Tandar, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 12, 2014</lastchanged_date>
  <firstreceived_date>March 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Anwar Tandar</investigator_full_name>
    <investigator_title>Assistant Professor (Clinical), Division of Cardiology</investigator_title>
  </responsible_party>
  <keyword>cardiovascular supplement</keyword>
  <keyword>cardiovascular disease</keyword>
  <keyword>coronary artery disease</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
